Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice.

[1]  V. Sukhatme,et al.  Statin‐induced muscle damage and atrogin‐1 induction is the result of a geranylgeranylation defect , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  D. Green,et al.  Caspase-7 deficiency protects from endotoxin-induced lymphocyte apoptosis and improves survival. , 2009, Blood.

[3]  T. Tsuji,et al.  Therapeutic effects of erythropoietin in murine models of endotoxin shock* , 2009, Critical care medicine.

[4]  A. Stalenhoef,et al.  Effects of ubiquinone (coenzyme Q10) on myopathy in statin users , 2008, Current opinion in lipidology.

[5]  Ji-xiang Zhang,et al.  A Role of Cell Apoptosis in Lipopolysaccharide (LPS)-induced Nonlethal Liver Injury in d-galactosamine (d-GalN)-sensitized Rats , 2008, Digestive Diseases and Sciences.

[6]  H. Redmond,et al.  Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. , 2008, Surgical infections.

[7]  M. Falagas,et al.  Statins for infection and sepsis: a systematic review of the clinical evidence. , 2008, The Journal of antimicrobial chemotherapy.

[8]  D. Thickett,et al.  Statins and sepsis. , 2008, British journal of anaesthesia.

[9]  C. Iadecola,et al.  Farnesyl transferase inhibitors induce neuroprotection by inhibiting Ha‐Ras signalling pathway , 2007, The European journal of neuroscience.

[10]  G. Arteel,et al.  Early growth response-1 contributes to galactosamine/lipopolysaccharide-induced acute liver injury in mice. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[11]  Wei Wei,et al.  Melatonin attenuates lipopolysaccharide (LPS)-induced apoptotic liver damage in D-galactosamine-sensitized mice. , 2007, Toxicology.

[12]  M. Kaneki,et al.  Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[13]  Kenji Suzuki,et al.  An inhibitor of c-Jun NH2-terminal kinase, SP600125, protects mice from D-galactosamine/lipopolysaccharide-induced hepatic failure by modulating BH3-only proteins. , 2007, Life sciences.

[14]  R. Talbert,et al.  Effectiveness of Statins in Reducing the Rate of Severe Sepsis: A Retrospective Evaluation , 2007, Pharmacotherapy.

[15]  C. Trautwein,et al.  The role of JNK2 in toxic liver injury. , 2006, Journal of Hepatology.

[16]  R. Hotchkiss,et al.  Apoptosis and caspases regulate death and inflammation in sepsis , 2006, Nature Reviews Immunology.

[17]  A. Hoes,et al.  Statin treatment and reduced risk of pneumonia in patients with diabetes , 2006, Thorax.

[18]  G. Spagnuolo,et al.  Inhibition of Ras/ERK1/2 signaling protects against postischemic renal injury. , 2006, American journal of physiology. Renal physiology.

[19]  Ping Li,et al.  Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis , 2006, The Lancet.

[20]  A. Anzueto,et al.  The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia , 2005, Respiratory research.

[21]  C. Weber,et al.  Statin Treatment After Onset of Sepsis in a Murine Model Improves Survival , 2005, Circulation.

[22]  M. Jeschke,et al.  Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats. , 2005, Journal of hepatology.

[23]  M. Kaneki,et al.  Inducible Nitric-oxide Synthase and NO Donor Induce Insulin Receptor Substrate-1 Degradation in Skeletal Muscle Cells* , 2005, Journal of Biological Chemistry.

[24]  J. Carcillo,et al.  Prolonged Lymphopenia, Lymphoid Depletion, and Hypoprolactinemia in Children with Nosocomial Sepsis and Multiple Organ Failure1 , 2005, The Journal of Immunology.

[25]  Eriko Tokunaga,et al.  S-Nitrosylation-dependent Inactivation of Akt/Protein Kinase B in Insulin Resistance* , 2005, Journal of Biological Chemistry.

[26]  V. Novack,et al.  Prior Statin Therapy Is Associated With a Decreased Rate of Severe Sepsis , 2004, Circulation.

[27]  C. Weber,et al.  HMG-CoA Reductase Inhibitor Simvastatin Profoundly Improves Survival in a Murine Model of Sepsis , 2004, Circulation.

[28]  R. Hotchkiss,et al.  INCREASED LYMPHOID TISSUE APOPTOSIS IN BABOONS WITH BACTEREMIC SHOCK , 2004, Shock.

[29]  F. Mach,et al.  Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. , 2003, Autoimmunity reviews.

[30]  Robert Kleemann,et al.  Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterol–Lowering Effect in APOE*3-Leiden Transgenic Mice: Evidence for Antiinflammatory Effects of Rosuvastatin , 2003, Circulation.

[31]  V. Gahtan,et al.  Noncholesterol-Lowering Effects of Statins , 2003, Vascular and endovascular surgery.

[32]  Anat Biegon,et al.  The Ras Inhibitor S-Trans, Trans-Farnesylthiosalicylic Acid Exerts Long-Lasting Neuroprotection in a Mouse Closed Head Injury Model , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  N. Hagiwara,et al.  Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. , 2002, British journal of clinical pharmacology.

[34]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[35]  U. Laufs,et al.  HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species , 2001, Hypertension.

[36]  R. Hotchkiss,et al.  Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans1 , 2001, The Journal of Immunology.

[37]  A. Iguchi,et al.  A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. , 2001, Atherosclerosis.

[38]  T. Takamura,et al.  Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. , 2000, The Journal of pharmacology and experimental therapeutics.

[39]  J. Deanfield,et al.  Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. , 2000, Journal of the American College of Cardiology.

[40]  J. Raymond,et al.  Expression of a Dominant‐Negative Mutant of p21ras Inhibits Induction of Nitric Oxide Synthase and Activation of Nuclear Factor‐κB in Primary Astrocytes , 2000 .

[41]  D. Remick,et al.  Endotoxin, sepsis, and the primrose path. , 1999, Shock.

[42]  R. Hotchkiss,et al.  Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. , 1999, Critical care medicine.

[43]  H. Jaeschke,et al.  Activation of caspase 3 (CPP32)-like proteases is essential for TNF-alpha-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. , 1998, Journal of immunology.

[44]  C. Der,et al.  Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? , 1997, Biochimica et biophysica acta.

[45]  K. Feingold,et al.  Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters. , 1997, Journal of lipid research.

[46]  C. Natanson,et al.  Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. , 1997, Critical care medicine.

[47]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[48]  K. Feingold,et al.  Discordant regulation of proteins of cholesterol metabolism during the acute phase response. , 1995, Journal of lipid research.

[49]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[50]  J. Taylor,et al.  Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. , 1993, Journal of lipid research.

[51]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. , 2004, Journal of the American College of Cardiology.